International audienceThe BRAF proto-oncogene serine/threonine-protein kinase, known as BRAF, belongs to the RAF kinase family. It regulates the MAPK/ERK signalling pathway affecting several cellular processes such as growth, survival, differentiation, and cellular transformation. BRAF is mutated in ~8% of all human cancers with the V600E mutation constituting ~90% of mutations. Here, we have used quantitative mass spectrometry to map and compare phosphorylation site patterns between BRAF and BRAF V600E. We identified sites that are shared as well as several quantitative differences in phosphorylation abundance. The highest difference is phosphorylation of S614 in the activation loop which is ~5fold enhanced in BRAF V600E. Mutation of S614 ...
Many driver mutations in cancer are specific in that they occur at significantly higher rates than -...
Gene mutations can induce cellular alteration and malignant transformation. Development of many type...
Class 3 mutations in B-Raf proto-oncogene, Ser/Thr kinase (BRAF), that result in kinase-impaired or ...
International audienceThe BRAF proto-oncogene serine/threonine-protein kinase, known as BRAF, belong...
BRAF is a serine/threonine protein kinase that functions as a component of the RAS/RAF/MEK/ERK signa...
BRAF is a serine/threonine protein kinase that functions as a component of the RAS/RAF/MEK/ERK signa...
BRAF is a component of the RAF/MEK/ERK signalling cascade which controls fundamental cellular activi...
The RAF kinase family is essential in mediating signal transduction from RAS to ERK. BRAF constituti...
The BRAF<sup>V600E</sup> mutation is found in approximately 6% of human cancers and mimics the phosp...
(L597V)BRAF mutations are acquired somatically in human cancer samples and are frequently coincident...
ABSTRACT: Substitution mutations in the BRAF serine/threonine kinase are found in a variety of human...
Oncogenic mutations in the BRAF kinase occur in 6-8% of nonsmall cell lung cancers (NSCLCs), account...
BRAF is a cytoplasmic protein kinase, which activates the MEK-ERK signalling pathway. Deregulation o...
BRAF is a cytoplasmic protein kinase, which activates the MEK-ERK signalling pathway. Deregulation o...
Activating mutations in the MAPK pathway are prevalent drivers of several cancers. The chief consequ...
Many driver mutations in cancer are specific in that they occur at significantly higher rates than -...
Gene mutations can induce cellular alteration and malignant transformation. Development of many type...
Class 3 mutations in B-Raf proto-oncogene, Ser/Thr kinase (BRAF), that result in kinase-impaired or ...
International audienceThe BRAF proto-oncogene serine/threonine-protein kinase, known as BRAF, belong...
BRAF is a serine/threonine protein kinase that functions as a component of the RAS/RAF/MEK/ERK signa...
BRAF is a serine/threonine protein kinase that functions as a component of the RAS/RAF/MEK/ERK signa...
BRAF is a component of the RAF/MEK/ERK signalling cascade which controls fundamental cellular activi...
The RAF kinase family is essential in mediating signal transduction from RAS to ERK. BRAF constituti...
The BRAF<sup>V600E</sup> mutation is found in approximately 6% of human cancers and mimics the phosp...
(L597V)BRAF mutations are acquired somatically in human cancer samples and are frequently coincident...
ABSTRACT: Substitution mutations in the BRAF serine/threonine kinase are found in a variety of human...
Oncogenic mutations in the BRAF kinase occur in 6-8% of nonsmall cell lung cancers (NSCLCs), account...
BRAF is a cytoplasmic protein kinase, which activates the MEK-ERK signalling pathway. Deregulation o...
BRAF is a cytoplasmic protein kinase, which activates the MEK-ERK signalling pathway. Deregulation o...
Activating mutations in the MAPK pathway are prevalent drivers of several cancers. The chief consequ...
Many driver mutations in cancer are specific in that they occur at significantly higher rates than -...
Gene mutations can induce cellular alteration and malignant transformation. Development of many type...
Class 3 mutations in B-Raf proto-oncogene, Ser/Thr kinase (BRAF), that result in kinase-impaired or ...